Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion ...
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...
"Our study shows that adding blinatumomab to consolidation chemotherapy keeps patients in remission and improves their survival. Based on what we found, this approach is the new standard of care for B ...
A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows. Researchers reveal explosive growth rates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback